Black at U.T., and Beyond

The Look 2020 A student set out to document the experiences of his Black classmates on their predominantly white campus. These are some of their stories. Photographs by Adraint Bereal Interviews by Patrice Peck ImageJordan Walters, center, with, from left, Joe Mason, Billy Summers and James Treuthardt. All of them are members of the Texas…

Details

Turn Your Newspaper Into a Basket

Months into the pandemic, you’ve most likely spent more time decluttering — and assessing the amount of joy sparked by forgotten discoveries — than you’d ever expected. Now you’re on to organizing, and baskets are a great way to collect all of those little things floating around your home. You can transform your newspaper into…

Details

Covid-19 Live Updates: Global Tracker

Here’s what you need to know: Video transcript Back transcript Republicans and Democrats Remain Divided on Stimulus Package Lawmakers were still at an impasse after meeting Friday, and President Trump’s advisers said they would recommend that he act on his own through an executive order. “It was a disappointing meeting. We reiterated in very strong…

Details

checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab

Denver–(Embargoed for 7 a.m. EST August 8, 2020) The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium. The study is presented by…

Details

Phase 3 eXalt3 study shows significantly longer progression-free survival

Denver–(Embargoed for 7 a.m. EST August 8, 2020)–Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib, according to a presentation at the International Association for the Study of Lung Cancer World Conference on…

Details

Addition of sintilimab to pemetrexed and platinum improved progression-free survival

Denver–(Embargoed for 7 a.m. EST August 8, 2020)–The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented…

Details